8-K: CirTran Secures $10M Equity Funding Facility

CirTran Corporation has entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. for up to $10 million in common stock sales.

Summary

• CirTran Corporation entered into a Standby Equity Purchase Agreement (Purchase Agreement) with YA II PN, Ltd. on December 22, 2025.
• The agreement grants CirTran the right, but not the obligation, to sell up to $10,000,000 of its common stock to YA over a 24-month period.
• The per-share purchase price for sales will be determined by the volume-weighted average price (VWAP) of CirTran's common stock, with the company having the option to establish a minimum acceptable price.
• CirTran is required to issue 3,846,154 shares of its common stock to YA in December 2026 as a commitment fee.
• Proceeds from stock sales are intended for working capital, general corporate purposes, and debt repayment.
• 50% of any proceeds received must be applied to reduce indebtedness (including accrued interest) to Tekfine, LLC.
• Tekfine, LLC has agreed to refrain from selling CirTran stock issued upon conversion of its notes during the term of the Purchase Agreement.
• Both YA and Tekfine have agreed not to engage in short sales or establish net short positions in CirTran's common stock during the agreement term.
• The Purchase Agreement will automatically terminate on the earlier of the 24-month anniversary of the effective date or when YA has purchased $10,000,000 in stock. CirTran can terminate with five trading days' prior written notice under certain conditions.

Sentiment

Score: 6

Explanation: The agreement provides a crucial funding mechanism for CirTran, addressing working capital and debt repayment needs. While it introduces potential dilution, the flexibility and protective clauses (like short-sale restrictions) offer a moderately positive outlook for securing necessary capital.

Positives

• Secures a flexible funding facility of up to $10,000,000, providing capital for working capital and general corporate purposes.
• Allows the company to control the timing and amount of stock sales, offering discretion based on market conditions and funding needs.
• Includes a commitment from Tekfine, LLC to refrain from selling converted notes during the agreement term, potentially reducing selling pressure.
• YA II PN, Ltd. and Tekfine, LLC are restricted from engaging in short sales of CirTran's common stock, which could help stabilize the stock price.

Negatives

• Potential for significant dilution to existing shareholders due to the issuance of up to $10,000,000 in common stock and the 3,846,154 commitment shares.
• The per-share purchase price is tied to VWAP, meaning sales could occur at lower prices if the stock declines, further exacerbating dilution.
• The company is obligated to apply 50% of proceeds to reduce indebtedness to Tekfine, LLC, limiting the discretionary use of funds.

Risks

• Dilution: Issuance of common shares could cause dilution to existing shareholders and significantly increase the outstanding number of common shares.
• Market Conditions: Actual sales of common stock to YA will depend on market conditions and the trading price of CirTran's common stock, which could impact the effective price per share received.
• Registration Statement Effectiveness: The company cannot request advances if a registration statement is not effective or if issuances would violate Principal Market rules.
• Ownership Limitation: YA is limited to beneficially owning no more than 4.99% of outstanding voting power or shares, which could restrict the size or frequency of advances.
• Regulatory Compliance: Failure to comply with SEC filing requirements or listing rules could impact the ability to utilize the facility.

Future Outlook

The company anticipates using the proceeds from this equity facility for working capital and general corporate purposes, including the reduction of existing debt. The ability to draw on this facility is contingent on market conditions and the effectiveness of a resale registration statement.

Management Comments

• We expect that any proceeds received by us from such sales to YA will be used for working capital and general corporate purposes, including the repayment of debt.

Industry Context

This type of standby equity purchase agreement, often referred to as an 'equity line of credit,' is a common financing tool for smaller public companies, particularly those listed on OTC markets, to secure access to capital without the immediate need for a traditional underwritten offering. It provides flexibility but can lead to significant dilution if the stock price declines during drawdowns. The restriction on short selling by the investor and a major creditor (Tekfine) is a notable protective measure for the company's stock price.

Comparison to Industry Standards

• Standby Equity Purchase Agreements (SEPAs) are a standard financing mechanism for micro-cap and small-cap companies, particularly those on the OTC Pink Open Market like CirTran (CIRX), which may have limited access to traditional debt or equity markets.
• The 4.99% ownership limitation for the investor (YA II PN, Ltd.) is a common provision in such agreements to prevent the investor from triggering beneficial ownership reporting requirements under Section 13(d) of the Exchange Act, which would require more extensive disclosures.
• The commitment fee, paid in shares, is typical for these types of facilities, compensating the investor for making capital available. The specific calculation (1.00% of commitment amount divided by VWAP) is a standard method.
• The requirement to file a resale registration statement is standard for private placements to institutional investors who intend to resell shares into the public market.
• The agreement by a major creditor (Tekfine, LLC) to refrain from selling shares converted from notes is a positive, but not universally present, feature that helps mitigate potential selling pressure often associated with such financing arrangements.

Corporate Governance

Related Party Transactions

• CirTran Corporation is required to apply 50% of any proceeds from stock sales to reduce indebtedness (including accrued interest) to Tekfine, LLC.
• Tekfine, LLC has agreed to refrain from selling CirTran stock issued on conversion of its notes during the term of the Purchase Agreement.
• Tekfine, LLC has agreed not to engage in any short sales of CirTran's common stock nor enter into any transaction that establishes a net short position during the term of the Purchase Agreement.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the issuance of new common stock. However, securing funding can support business operations and potentially enhance long-term value.
• Creditors (Tekfine, LLC): Will see 50% of capital raise proceeds applied to debt reduction, improving their position. Their agreement to not short sell also benefits the company.
• Employees, Customers, Suppliers: Improved financial stability from the funding facility could positively impact operational continuity and relationships.

Next Steps

• CirTran Corporation will file a registration statement with the SEC to register the resale of common stock by YA II PN, Ltd.
• The company will, at its discretion, issue and sell common stock to YA II PN, Ltd. over the next 24 months, subject to market conditions and registration statement effectiveness.
• CirTran will issue 3,846,154 commitment shares to YA II PN, Ltd. in December 2026.
• The company will apply 50% of any proceeds from stock sales to reduce indebtedness to Tekfine, LLC.

Key Dates

Recommendation

The Standby Equity Purchase Agreement provides CirTran with a flexible funding mechanism, which is a positive for a company seeking capital for working capital and debt reduction. The commitment from YA II PN, Ltd. and Tekfine, LLC to refrain from short selling offers some protection against immediate downward pressure. However, the potential for significant dilution from the issuance of up to $10 million in common stock, plus the commitment shares, and the reliance on market conditions for pricing, introduces considerable risk. Given the balance of securing necessary capital against the inherent dilution risk, a 'hold' recommendation is appropriate, advising investors to monitor the company's utilization of the facility and its impact on the share structure and financial performance.

Keywords

Standby Equity Purchase Agreement, Equity Line, Capital Raise, Dilution, Working Capital, Debt Repayment, SEC Filing, CIRX, YA II PN, Ltd., Tekfine LLC, Common Stock